bioAffinity Technologies, Inc.

16 articles with bioAffinity Technologies, Inc.

• bioAffinity Technologies Presents its Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

  12/6/2021

  bioAffinity Vice President of Research David Elzi, Ph.D., will discuss how bioAffinity successfully uses RNA interference to knock down expression of two genes that results in killing cancer cells with little or no effect on normal cells at Cell Bio.

• bioAffinity Technologies Announces Xavier T. Reveles Promoted to Vice President of Operations

  10/14/2021

  bioAffinity Technologies today announced that Xavier T. Reveles, MS, CG, has been promoted to Vice President of Operations.

• bioAffinity Technologies Announces Precision Pathology Services’ Validation of Novel Non-Invasive Early Lung Cancer Test

  9/14/2021

  bioAffinity Technologies announced that Precision Pathology Services has fully validated the clinical performance of CyPath ® Lung,

• bioAffinity Technologies to Present at 2020 American Society of Cell Biology Meeting

  11/10/2020

  bioAffinity Technologies , a privately held biotech company, today announced that its poster “Meso-tetra (4-carboxyphenyl) porphyrin (TCPP) is incorporated into cancer cells by the CD320 receptor and clathrin mediated endocytosis” will be presented during the session Cancer Therapy: Defining Therapeutic Targets and New Therapeutics at the American Society of Cell Biology’s Cell Bio Virtual 2020 - An Online ASCB|EMBO Mee

• bioAffinity Technologies Announces Dr. Martin Tammemägi to Chair Scientific and Medical Advisory Board

  9/29/2020

  bioAffinity Technologies , a privately held biotech company, today announced Martin Tammemägi , PhD, Professor Emeritus of Health Sciences at Brock University, will serve as Chairman of the bioAffinity Scientific and Medical Advisory (SMA) Board. “Dr. Tammemägi is exceptionally well respected and a leader in cancer epidemiology, lung cancer screening and cancer risk prediction modeling,” bioAffinity President and Chi

• Precision Pathology Services and bioAffinity Technologies Announce Initiation of CLIA Validation for Non-Invasive Early Lung Cancer Test

  8/12/2020

  bioAffinity Technologies , a privately held biotech company advancing cutting-edge cancer diagnostics, and Precision Pathology Services , a CAP/CLIA-certified anatomic and clinical pathology laboratory, announced initiation of CLIA validation for CyPath® Lung, a non-invasive flow

• bioAffinity Technologies Announces Poster Presentation at CYTO 2020 Conference

  8/4/2020

  bioAffinity Technologies Announces Poster Presentation at CYTO 2020 Conference

• bioAffinity Technologies Announces Closing of $5,000,000 Convertible Note Financing

  7/28/2020

  bioAffinity Technologies , a privately held biotech company, today announced it has closed a non-brokered, secured convertible note ("Note") financing for proceeds of $5,000,000.00 (the "Offering"). The proceeds from the Note are funding operations to advance the Company’s non-invasive CyPath® Lung cancer test and therapeutic research and development of novel drug candidates for the selective treatment of multiple cancers.

• Stephen Squinto, Ph.D., Named Vice Chairman of bioAffinity Technologies

  7/7/2020

  bioAffinity Technologies, a privately held cancer diagnostics and therapeutics company, today announced that Stephen Squinto, Ph.D., has been named Vice Chairman of the Company’s Board of Directors, and David Elzi, Ph.D., has been appointed Vice President of Research in recognition of Dr. Elzi’s pivotal role in the Company’s scientific discoveries related to cancer therapeutics.

• bioAffinity Cancer Research Laboratories Named for Philanthropist Harvey Sandler

  6/16/2020

  bioAffinity Technologies , a privately held biomedical company, today named its research laboratories in memoriam of Harvey Sandler, a businessman who used his considerable success to support research that advances diagnostic tests and targeted treatments for cancer. “It was due to Harvey’s initial investment that bioAffin

• bioAffinity Technologies Validation Trial for Non-Invasive Lung Cancer Test Results in High Sensitivity and Specificity

  6/10/2020

  bioAffinity Technologies, a privately held biotech company, today announced its test validation trial for CyPath® Lung resulted in specificity of 88% and sensitivity of 82%, similar to far more invasive procedures commonly used to diagnose lung cancer.

• Company Profile for bioAffinity Technologies, Inc.

  6/10/2020

  bioAffinity Technologies, Inc. is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment.

• bioAffinity Technologies Joins National Lung Cancer Roundtable

  10/11/2019

  bioAffinity Technologies, a privately held biotech company, today announced that it has been accepted as a member of the American Cancer Society’s National Lung Cancer Roundtable (NLCRT), a collaborative whose membership is focused on reducing both the incidence of lung cancer and mortality rates from the disease.

• bioAffinity Technologies Opens Test Validation Trial of CyPath® Lung

  7/17/2018

  bioAffinity Technologies announced it has commenced its test validation trial for CyPath® Lung, an advanced flow cytometry test for the early detection of lung cancer. 

• bioAffinity Technologies And UT Health Science Center Collaborate To Optimize Cancer Diagnostics And Therapeutics

  7/13/2016

• bioAffinity Technologies Expands with Launching of New Company OncoSelect

  6/24/2016